RCT: Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

Ivosidenib and azacitidine showed clinical benefit as compared with placebo and azacitidine in patients with newly diagnosed IDH1-mutated AML, a difficult-to-treat population. https://t.co/6K6mWJdd2V pic.twitter.com/qOwOvHcV4j

— NEJM (@NEJM) April 20, 2022